Eli Lilly and Company (NYSE:LLY) Stock Falls 1.3% – Time to Sell?

Eli Lilly and Company (NYSE:LLY) shares dropped 1.3% during trading on Tuesday. The company traded as low as $1,158.41 and last traded at $1,167.0070. 1,836,608 shares changed hands during trading, a decline of 38% from the average session volume of 2,952,272 shares. The stock had previously closed at $1,182.62.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: New analyses support Omvoh (mirikizumab) as a potential higher-standard treatment for inflammatory bowel disease. In the LUCENT-2 ulcerative-colitis study, 27.7% of treated patients achieved comprehensive corticosteroid-free disease control, while 20.4% of Crohn’s disease patients in VIVID-1 achieved corticosteroid-free deep remission. Benefits were also observed among patients who had previously failed biologic therapy, strengthening Omvoh’s commercial positioning. Omvoh composite outcomes data
• Positive Sentiment: Retatrutide, Lilly’s experimental triple-agonist obesity drug, remains a major future growth opportunity after reportedly producing substantial weight loss in late-stage testing. A potential regulatory filing in early 2027 gives investors another catalyst beyond Mounjaro and Zepbound, although approval is not guaranteed. Retatrutide availability
• Positive Sentiment: Lilly is broadening its pipeline through oncology and immunology activity, including a collaboration evaluating Adlai Nortye’s investigational AN4035 with cetuximab, plus updates involving donanemab and lebrikizumab. These programs add longer-term diversification beyond obesity medicines. Adlai Nortye collaboration
• Neutral Sentiment: Lilly will release third-quarter 2026 results on October 29. Investors will focus on demand for its GLP-1 products, supply expansion, margins and whether management maintains its full-year EPS outlook. Lilly third-quarter earnings date
• Negative Sentiment: After a powerful multi-year rally and a market capitalization above $1 trillion, valuation and profit-taking could limit further upside. Commentary also raises the possibility of a stock split, but a split would not change Lilly’s underlying earnings or intrinsic value. Eli Lilly stock split analysis

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. Bank of America boosted their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a research note on Monday, September 28th. Guggenheim lifted their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a report on Friday, September 18th. Leerink Partners boosted their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,313.43.

Eli Lilly and Company Stock Up 3.7%

The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The business has a 50-day simple moving average of $1,177.42 and a two-hundred day simple moving average of $1,104.28. The company has a market cap of $1.18 trillion, a price-to-earnings ratio of 42.15, a PEG ratio of 1.50 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the prior year, the firm earned $6.31 EPS. Eli Lilly and Company’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 34.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Donald Zakrowski sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LLY. BlackRock Inc. boosted its position in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares during the last quarter. State Street Corp raised its position in Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares during the last quarter. Bank of America Corp DE purchased a new position in Eli Lilly and Company during the 2nd quarter worth $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Eli Lilly and Company by 1.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock valued at $8,647,153,000 after purchasing an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC grew its stake in Eli Lilly and Company by 7.9% in the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after acquiring an additional 400,538 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.